#	Pagina
attuale pagina	/open-h2020/projects/217853/index.html

Opendata, web and dolomites

ONCOSMART SIGNED

ONCOlogic patient profiling and personalized treatment through SMART bedside diagnostics

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

ONCOSMART project word cloud

Explore the words cloud of the ONCOSMART project. It provides you a very rough idea of what is the project "ONCOSMART" about.

protected validate genomic immunotherapies commercialisation 2018 pending aml seal certificate samples anticancer releasing industrialise vitro interactions power standardised aid individual november appropriate china predicting therapies trials tumor molecular diagnostic solid automated live 24 ml tested 2019 treatments alone performance determines cellply freedom engineered additional ivd captured tumors analytical marrow doctors shown first predictive profiling bone operate cell combination submitted effectiveness made leukemia platform 48 patients cells hematologic patient cancer clinical hours functional pct innovative chemo blood proving suitable excellence oncosmart multiple drugs superior italian contained therapy patent extended guide 2017 issued families

Project "ONCOSMART" data sheet

The following table provides information about the project.

Coordinator	CELLPLY SRL Organization address address: VIA FONDAZZA 53 city: BOLOGNA postcode: 40125 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Italy [IT]
Project website	https://cellply.com/horizon-2020/
Total cost	3˙348˙500 €
EC max contribution	2˙343˙950 € (70%)
Programme	1. H2020-EU.3. (PRIORITY 'Societal challenges) 2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs) 3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
Code Call	H2020-SMEInst-2018-2020-2
Funding Scheme	SME-2
Starting year	2018
Duration (year-month-day)	from 2018-09-01 to 2021-02-28

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	CELLPLY SRL CELLPLY SRL Organization address address: VIA FONDAZZA 53 city: BOLOGNA postcode: 40125 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IT (BOLOGNA)	coordinator	2˙343˙950.00

Map

Project objective

ONCOSMART is the first In-Vitro Diagnostic (IVD) system that determines the effectiveness of anticancer drugs for a specific patient, testing live cell response to one or multiple cancer drugs. ONCOSMART analyses bone marrow or blood samples from a specific cancer patient, providing the results within 24-48 hours. This “functional profiling” approach has shown superior performance in non-automated systems to current molecular/genomic methods in predicting individual patient’s response to anticancer treatments. ONCOSMART is a fully-automated and standardised functional profiling platform that is made available to doctors and researchers to identify the most suitable cancer therapy for individual patients and also aid patient selection in clinical trials. The innovative platform analyses the interactions between anticancer drugs and live tumor cells contained in 2 mL of blood or bone marrow samples. Cellply has freedom to operate and protected ONCOSMART with 2 patent families issued in EU, US and China, 1 issued in EU, 1 pending PCT application, 2 pending Italian applications. Additional value is captured by 4 patent applications to be submitted in 2018-2019. ONCOSMART can test anticancer drugs including targeted, chemo and immunotherapies alone or in combination. The test results guide the selection of: 1) the appropriate therapy for a specific patient; 2) cancer patients for specific clinical studies; 3) cancer patients for novel therapies in clinical development. The platform has been fully-engineered and tested on leukemia patients (AML), proving its predictive power, and is extended to other hematologic and solid tumors in future developments. Within this project, CellPly has the goal to industrialise the platform, validate its analytical and clinical performance and support the first commercialisation activities releasing the platform for research first, then for clinical use. Seal of Excellence certificate obtained on November 2017.

Deliverables

List of deliverables.
Communication Strategy Guide	Documents, reports	2020-01-14 14:21:31
Project visual identity and website	Websites, patent fillings, videos etc.	2020-01-14 14:21:32

Take a look to the deliverables list in detail: detailed list of ONCOSMART deliverables.

Publications

List of publications.
year	authors and title	journal	last update
2019	Alice Bettelli, Rita Ruggiano, Silvia Bocchi, Laura Rocchi, Andrea Faenza, Enrica Borsi, Carolina Terragna, Elena Zamagni, Marina Martello, Marco Bettelli, Laura Rambelli, Viviana Guadagnuolo, Nicola Pecorari, Luca Giulianelli, Matteo Pisani, Dario Biscarini, Michele Cavo, Roberto Guerrieri and Massimo Bocchi. Inter-Cell Networking Profiling Enables Comprehensive Characterization of Immune-Mediated Activity of Anti-CD38 Therapy through Ex-Vivo Analysis of Multiple Myeloma Patients. published pages: , ISSN: , DOI:	Blood	2019-11-08

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ONCOSMART" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ONCOSMART" are provided by the European Opendata Portal: CORDIS opendata.